NCT01354938 - Outcome Study to Evaluate Klaricid XL® (Clarithromycin Modified Release) in Patients With Acute Exacerbation of Chronic Bronchitis | Biotech Hunter

Enrollment

220

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions

Bronchitis

Interventions

DRUG

Clarithromycin modified release 500 mg

Clarithromycin modified release 500 mg was prescribed. The dosage given was either 1 tablet or 2 tablets once a day, depending on the severity of the treatment.

Trial Locations (28)

60000

Site Ref # / Investigator 54044, Multan

Unknown

Site Ref # / Investigator 54037, Peshawar

Site Ref # / Investigator 54026, Faisalabad

Site Ref # / Investigator 54028, Faisalabad

Site Ref # / Investigator 54029, Faisalabad

Site Ref # / Investigator 54015, Hyderābād

Site Ref # / Investigator 54016, Hyderābād

Site Ref # / Investigator 54017, Hyderābād

Site Ref # / Investigator 54018, Hyderābād

Site Ref # / Investigator 54035, Islamabad

Site Ref # / Investigator 54002, Karachi

Site Ref # / Investigator 54003, Karachi

Site Ref # / Investigator 54004, Karachi

Site Ref # / Investigator 54005, Karachi

Site Ref # / Investigator 54006, Karachi

Site Ref # / Investigator 54007, Karachi

Site Ref # / Investigator 54009, Karachi

Site Ref # / Investigator 54010, Karachi

Site Ref # / Investigator 54013, Karachi

Site Ref # / Investigator 54019, Lahore

Site Ref # / Investigator 54020, Lahore

Site Ref # / Investigator 54022, Lahore

Site Ref # / Investigator 54023, Lahore

Site Ref # / Investigator 54040, Multan

Site Ref # / Investigator 54043, Multan

Site Ref # / Investigator 55270, Multan

Site Ref # / Investigator 55273, Peshawar

Site Ref # / Investigator 54033, Rawalpindi